Bacteriophage Effects on Pseudomonas Aeruginosa

Bacteriophages Effects on Pseudomonas Aeruginosa Presents in Sputum of Cystic Fibrosis (CF) Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01818206

Acronym

MUCOPHAGES

Enrollment

Registered

2013-03-26

Start date

2012-02-29

Completion date

2012-04-30

Last updated

2013-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

Cystic Fibrosis, Bacteriophages, Pseudomonas aeruginosa, Sputum

Brief summary

Pulmonary phage therapy to treat bacterial infections of the respiratory tract have been investigated in animals. The aim of the present study is to evaluate the efficacy of bacteriophages in infecting Pseudomonas aeruginosa (PA) strains present in sputum samples. A cocktail of 10 bacteriophages will be applied on 60 sputum samples obtained from cystic fibrosis (CF) patients during 6 hours.We will determine the bacteria and bacteriophages strains in sputum samples collected. Then the sensitivity of individual colony will be tested.

Interventions

OTHERCollection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.

Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Years to No maximum

Healthy volunteers

Inclusion criteria

* Informed consent * Affiliated or benefit from a disease insurance regimen * Men and women * Aged from at least 6 years old * Confirmed Diagnosis of cystic fibrosis based on presence of 2 mutations of CFTR gene and/or 2 positive tests of sweat chloride and/or 2 measures of pathologic difference of nasal potential associated to cystic fibrosis clinical signs. * Patients able to produce sputum * Pseudomonas aeruginosa Chronic infected patients

Exclusion criteria

* Simultaneous participation to another project on anti-infection, anti-inflammatory or modificating agents * Subjet in exclusion period * Law protected patient * Realisation of sputum production is contra-indicated

Design outcomes

Primary

Measure	Time frame
Pseudomonas aeruginosa (PA) strains counts after 6 hours in presence of bacteriophage	after 6 hours in presence of bacteriophage

Secondary

Measure	Time frame
Pseudomonas aeruginosa (PA) strains counts after 24 hours in presence of bacteriophage	after 24 hours in presence of bacteriophage
Bacteriophage counts after 6 hours incubation within sputum samples	after 6 hours incubation within sputum samples
Sensitivity of individual Pseudomonas aeruginosa (PA) colonies to bacteriophages	Sensitivity of individual PA colonies to bacteriophages

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026